Generics and Novel Drugs to Fuel Growth in the Pharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc.

Share Article

Growth in the worldwide pharmaceuticals industry is anticipated from the development of new and improved drugs. The industry's landscape would be further metamorphosized by the increasing share of generic pharmaceuticals and evolution of biopharmaceuticals, along with factors such as increasing outsourcing activities related to production and research operations, and compliance with various global trade regulations.

Pharmaceuticals is a dynamic industry influenced by scientific advancements in the drug discovery sector, and is driven by the improved understanding of disease genesis. Demand for pharmaceuticals is dependent on the need for innovative treatments addressing unmet medical needs, favorable demographics, preferential placement on government and managed care formularies, consumerism and physician prescription behavior. An aging global population, increasing life expectancies, and availability of insurance coverage are anticipated to enhance consumption of pharmaceutical products for a wide range of diseases.

Brazil, Russia, India and China (BRIC) countries, supported by favorable economic conditions, are anticipated to foster growth in various individual sectors of the pharmaceutical industry. In Asia-Pacific, low purchasing capacity of the population and government restrictions on healthcare spending are increasing sales in the low-cost generic drugs market. Among the Asian markets, China has emerged as a potential region with vast opportunities for global pharmaceutical majors. Growth in the market is likely to be driven by the increasing number of drugs in the pipeline, lifestyle changes and expanding proportion of the elderly, with sectors such as CNS (central nervous system), alimentary/metabolism products and cardiovascular agents witnessing maximum demand. India's growth, in particular, is anticipated to be exceptional, owing to the nation's strength as a low-priced economy, with lenient patent regime and availability of skilled workforce.

A steady rise in the spending for research and development operations is promoting the development of new and improved drugs. Major drugs that are anticipated to drive sales and manufacture of intermediates and Active Pharmaceutical Ingredients (APIs) include anti-inflammatory drugs, anti-infectives and antibiotics, respiratory drugs, central nervous system drugs, cardiovascular system drugs, including the rapidly growing sector of anti-diabetics. However, the developmental activities are faced with paucity of funds, owing to the need for sustained investment of large funds for long periods of time. Cardiovascular drugs represents the leading category in the global pharmaceuticals market, driven by rising incidence of obesity, unhealthy lifestyles, and smoking.

Generic drugs market across various countries, both developed and developing, is witnessing rapid growth, fostered by the need for providing low-cost alternative to expensive yet life-saving drugs. The vast potential of this market is attracting multinationals to foray into the production and marketing of generic versions of patented pharmaceutical products. Increasing production of generics in developing countries, often involving patent violations, is allowing local consumers to gain access to drugs that were earlier out of bounds for them. With several patents set for expiry in the near future, the market for generic drugs in the region is promising. United States and Europe continue to promote generics production, primarily to overcome the rising healthcare expenses in these countries.

The report titled "Pharmaceuticals: A Global Outlook" provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird's eye view of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as, patent expiry of blockbuster global drugs, rising demand for old age related medications and cardiovascular drugs, and the rise of biogenerics, among others. Punctuated with 18 statistically rich tables, the global market discussion offers special preludes to major market segments, such as, Prescription Drugs, Anti-Depressants, Cholesterol Drugs, and CNS Drugs, among others. Annotated with quantitative analysis and research findings, the discussion on the US market contains 46 market data tables designed to give the reader a macro level understanding of the market. Other regional markets covered include Canada, Japan, Western Europe, and China, among others. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 3,083 companies worldwide.

For more details about this research report, please visit
http://www.strategyr.com/Pharmaceuticals_Industry_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press @ StrategyR.com
Web Site http://www.StrategyR.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website